Sartorius Solutions for Monoclonal Antibody (mAb) Therapy Discovery and Development
More Insight, Better Decisions
Therapeutic antibodies have recently emerged as one of the most successful immunotherapy strategies for the treatment of both hematologic cancers and solid tumors. Because antibody therapy offers the promise of better specificity and safety than many other cancer treatments, this class of biologics is currently one of the fastest growing types of cancer therapies.
To mount a successful monoclonal antibody (mAb)-based discovery and development program for cancer, whether developing therapeutic antibodies or antibody drug conjugates, you need technologies that allow rapid identification and characterization of candidate molecules to identify those with superior target reactivity and optimized functionality. Sartorius offers information-rich solutions for development of antibody therapeutics that enable tracking of complex biological processes at unprecedented speed, depth, and scale. Accelerate your biotherapeutic development and still have peace of mind. Our unique and innovative solutions for discovery and development of mAb therapies streamline the workflow and increase productivity, while still providing confidence in the choice, quality and integrity of your mAb cancer therapy.
A reliable mAb discovery and development program lays a strong foundation for a successful mAb production and mAb manufacturing process. Explore how Sartorius can support your mAb therapy programs.
NEW INFOGRAPHIC
Challenges and Solutions for Developing New Monoclonal Antibodies
Unprecedented advances in medicine are delivering remarkable results for some patients. Recent approvals of CAR T therapies and new approaches in regenerative medicine, for example, exemplify Monoclonal antibodies (mAbs) used for immunotherapy stimulate the immune system to mount a response to target antigens. These powerful therapeutics are being used to...
WEBINAR
Body Feed Filtration – the Novel Method for Rapid Harvesting of Mammalian Cell Cultures
Register now and learn about an innovative new method for tackling the first step into monoclonal antibody (mAb) purification - body feed filtration.
WEBINAR
Accelerating Nanobody Discovery Workflows with High-Throughput Flow Cytometry
In this webinar, Dr. Pieter Kennis discusses how nanobodies – small, single-domain antibody fragments that retain full antigen-binding capabilities and the properties of heavy-chain antibodies – and nanobody discovery and screening platforms exploit high-throughput flow cytometry to increase the throughput of nanobody screening campaigns.
Our solutions
Cell Analysis Platforms
Sartorius’s cell analysis platforms offer unique, high-capacity solutions for characterizing immune phenotype and function at unprecedented speed, depth, and scale to provide information-rich data for tracking complex biological processes. Our innovative technologies generate deeper, more relevant data on phenotype, activation, and function, using less of your precious samples. Unlike other approaches that require multiple assays or time points, our technologies reduce variability by delivering more data per time point, or across multiple time points, in the same context, under the same conditions. Using our comprehensive analysis and visualization capabilities for biologics characterization, you will have access to actionable results, faster.
IncuCyte® Live-Cell Analysis System
Enables real-time, live-cell imaging and analysis directly inside your incubator. Measure kinetic effects of your antibody treatment on target cells without ever having to remove cells from the incubator.
Intellicyt® iQue3
High-throughput, suspension cell and bead analysis platform for rapidly profiling of cell phenotype and function in therapeutic antibody discovery workflows. Ideal for those screens where cells are precious or limited in number, the iQue3 is the fastest way to generate high-content data from small samples.
mAb Purification Mini Platform
Sartorius’s mAb purification mini platform is ideal for small-scale purification of your mAb from up to 1 L of cell culture supernatant.
The mini platform includes up to seven steps to take you through all the workflows necessary for mAb purification: cell clarification and filtration, antibody capture by affinity chromatography, purification step(s), concentration, and sterile filtration.
Each of our application steps maximizes output for the next step in the workflow, to support a seamless mAb purification process with maximum output.
How we ensure confidence for your mAb discovery and development program
- Multifactorial, information-rich results
- Faster results, improved productivity
- More meaningful and biologically relevant insights
- Higher confidence in quality, purity, and integrity of you product
Microsart® AMP Mycoplasma Kit
Ensure your results are from your cells, not contamination. Screen your cultures with our real-time PCR kit for mycoplasma contamination.
Microsart® RESEARCH Bacteria Kit
Provides rapid detection of total bacteria within 2½ h. Use Microsart® RESEARCH Bacteria for fast and reliable real-time PCR-based detection of bacterial contamination in cell cultures or cell culture supernatants.
MYCAP® CCX Cell Expansion System
Reliable aseptic technique for cell culture expansion, MYCAP® CCX has a revolutionary closed design that ensures media feed, inoculation, sampling, and transfers are done aseptically—without the need for a biosafety cabinet.
Sample Preparation
Sartorius’s lab products for sample preparation are scalable and enable reproducible procedures. Our products cover a spectrum from weighing to sedimentation solutions to ultrafiltration units.
Optimize your sample preparation for accurate and reliable results.
mAb Therapy Discovery & Development Workflow
Molecule Development
Candidate mAb therapy discovery and development begins with a comprehensive understanding of the biological and molecular pathways underlying disease states and a full understanding of how your candidates interrupt these processes.
You need powerful tools that can deliver multifactorial results. Sartorius’s cell analysis platforms and laboratory essentials offer unique, high-capacity solutions for molecule development, from characterizing disease pathways to understanding candidate molecule function.
Screen cells in suspension and targets in their natural conformation and get better information with simultaneous acquisition of both antigen binding and cross-reactivity.
Target Identification/Validation
Library Screening
Lead Optimization
Candidate Characterization
Cell-Line Development
The success of your mAb development program hinges on early development of dedicated cell lines and identification of your best performers. Sartorius offers cell line development services if your plans call for outsourcing, and solutions for cell line development that you can use in-house.
Our products, services, and technologies offer innovative solutions to enable multiparametric assessment of clones, from protein concentration to cell health and viability, to rapidly and efficiently identify and rank your best performing clones.
See how clone ranking and selection can change dramatically by multiparametric assessment (IgG titer, IgG titer per cell, cell density and cell viability) of your clones, so you can screen more clones in less time and make decisions sooner.
Before market release, fully characterize your cell lines and cell banks. Our combined solutions of advanced analytical and biosafety testing with high-resolution and sensitivity enable you to precisely assess all properties of your cell lines. Then, mitigate your risk and ensure the safety and quality of your biological product with our solutions for homogeneous master cell banks (MCB) and working cell banks (WCB).
Gene Cloning
Cell-Line Selection/Identification
Cell-Line Characterization
Cell Banking
mAb Resources
NEW WHITE PAPER
Analytical Power Tools Open Upstream Bioprocessing Bottlenecks
Cy-Clone™ PLUS, a validated assay kit accelerates human mAb production cell-line generation, significantly reducing the time to industrial-scale productivity.